- CAR-T cell therapy, an innovative immunotherapy that reprograms a patient’s T-cells to recognize and attack cancer cells, is increasingly becoming a critical treatment approach for hematologic malignancies across the MEA region due to its high efficacy, personalized nature, and ability to induce durable remissions in relapsed or refractory cases
- The rising demand for CAR-T cell therapy is primarily fueled by the growing prevalence of blood cancers such as leukemia and lymphoma, increasing awareness among healthcare providers and patients, and expanding clinical research in the MEA region
- U.A.E. dominated the MEA CAR-T cell therapy treatment market with the largest revenue share of 26.8% in 2024, characterized by strong healthcare infrastructure, early adoption of innovative treatments, and significant investment in personalized cancer therapies
- Israel is expected to be the fastest growing country in the MEA CAR-T cell therapy treatment market with a projected CAGR of 17.5% from 2025 to 2032, driven by cutting-edge research in immuno-oncology, an expanding biotech ecosystem, and high clinical trial activity in cell and gene therapy
- Antigens on hematologic malignancies segment dominated the MEA CAR-T cell therapy treatment market with a market share of 66.4% in 2024, fueled by the success of CAR-T therapies for blood cancers such as leukemia, lymphoma, and multiple myeloma
